DARE logo

DARE Dare Bioscience, Inc.

NASDAQ · Biotechnology · Healthcare

$0.41
-0.04 (-9.87%)

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of …

Market Cap: $8.01Mdarebioscience.com

Price

No data yet.

Social Signal Score

49
5d
—
30d
47
9 mentions
—
60d
48
11 mentions
—
90d
52
16 mentions
—
news: 16

Analyst Ratings

6 analysts
Buyconsensus
Strong Buy 0Buy 6Hold 0Sell 0Strong Sell 0
Avg price target$1.5+268.2%
Low $1Median $1.5High $2
Current Consensus

Revenue

$47.6K-93.78%
$-1.83M$2.11M$6.06M$10.00M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-1.67
$-2.47–$-0.87
2 analysts
FY2026
$-0.68
$-0.83–$-0.46
2 analysts
FY2027
$-0.50
$-0.64–$-0.31
3 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Sabrina Martucci Johnson
Sector
Healthcare
Industry
Biotechnology
Employees
23
Beta
1.15
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
-13.60
darebioscience.com